Skip to main content
SpringerLink
Log in

Valproate-Induced Hyperammonemic Encephalopathy

  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

Valproic acid (VPA) is an effective anticonvulsant useful in many types of epilepsy and, although it is usually well tolerated, it has been associated with many neurological and systemic side effects. Among these, one of the most important is VPA-induced hyperammonemic encephalopathy (VHE): its typical signs are acute onset of impaired consciousness, focal neurologic symptoms, and increased seizure frequency. The pathogenesis of VHE is still unclear, but it has been suggested that hyperammonemia can produce encephalopathy via inhibition of glutamate uptake by astrocytes which may lead to potential neuronal injury and perhaps cerebral edema. Glutamine production is increased, whereas its release is inhibited in astrocytes exposed to ammonia. The elevated glutamine increases intracellular osmolarity, promoting an influx of water with resultant astrocytic swelling. This swelling could compromise astrocyte energy metabolism and result in cerebral edema with increased intracranial pressure. Moreover, VHE seems to be more frequently in patients with carnitine deficiency or with congenital urea cycle enzymatic defects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Appleton, R.E., Farrel, K., and Applegarth, D.A. (1990). The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can. J. Neurol. Sci. 17:145-148.

    Google Scholar 

  • Bicknese, A.R., May, W., and Hickey, W.F. (1992). Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. Ann. Neurol. 32:767-775.

    Google Scholar 

  • Blindauer, K.A., Harrington, G., Morris, G.L., III, and Ho, K. C. (1998). Fulminant progression of demyelinating disease after valproate-induced encephalopathy. Neurology 51:292-295.

    Google Scholar 

  • Bryant, A.E., and Dreifuss, F.E. (1996). Valproic acid hepatic fatalities. III: U.S. experience since 1986. Neurology 46:465-469.

    Google Scholar 

  • Chapoy, P.R., Angelini, C., Brown, W.J., Stiff, J.E., Shug, A.L., and Cederbaum, S.D. (1980). Systemic carnitine deficiency-A treatable inherited lipid-storage disease presenting as Reye's syndrome. N. Engl. J. Med. 303:1389-1394.

    Google Scholar 

  • Chayasirisobbon, S., and Russel, M. (1983). Valproic acid and intractable seizures in severely brain-damaged patients. Neurology 33:99-101.

    Google Scholar 

  • Coulter, D.L., and Allen, R.J. (1980). Secondary hyperammonemia. A possible mechanism for valproate encephalopathy. Lancet i:1310-1311.

    Google Scholar 

  • Coulter, D.L., Allen, R.J., and Arbor, A. (1981). Hyperammonemia with valproic acid therapy. J. Pediatr. 99:317-319.

    Google Scholar 

  • Dodson, W.E., and Tasch, V. (1981). Pharmacology of valproic acid in children with severe epilepsy: Clearance and hepatotoxicity. Neurology 31:1047-1050.

    Google Scholar 

  • Dreifuss, F.E. (1983). Lennox-Gastaut syndrome. In: Dreifuss, F.E. (ed.), Pediatric Epileptology. Classification and Management of Seizures in the Child, Wright, Boston, MA.

    Google Scholar 

  • Duarte, J., Macias, S., Coria, F., Fernandez, E., and Clavaria, L.E. (1993). Valproate-induced coma: Case report and literature review. Ann. Pharmacother. 27:582-583.

    Google Scholar 

  • Fraser, C.M., Sills, G.J., Forrest, G., Thompson, G.G., and Brodie, M.J. (1999). Effects of antiepileptic drugs on glutamine synthetase activity in mouse brain. Br. J. Pharmacol. 126:1634-1638.

    Google Scholar 

  • Gago, M.C., Novo, I., and Segade, S.R. (1990). Effects of valproic acid on the urea cycle and carnitine metabolism. Int. Pediatr. 5:54-56.

    Google Scholar 

  • Gidal, B.E., Inglese, C.M., Meyer, J.F., Pitterle, M.E., Antonopoulos, J., and Rust, R.S. (1997). Diet-and valproate-induced transient hyperammonemia: Effect of L-carnitine. Pediatr. Neurol. 16:301-305.

    Google Scholar 

  • Haidukewych, D., John, G., Zielinski, J.J., and Rodin, E.A. (1985). Chronic valproic acid therapy and incidence of increases in venous plasma ammonia. Ther. Drug Monit. 7:290-294.

    Google Scholar 

  • Hamer, H.M., Knake, S., Schomburg, U., and Rosenow, F. (2000). Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 54:230-232.

    Google Scholar 

  • Honeycutt, D., Callahan, K., Rutledge, L., and Evans, B. (1992). Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology 42:666-668.

    Google Scholar 

  • Kay, J.D., Hilton-Jones, D., and Hyman, N. (1986). Valproate toxicity and ornithine carbamoyltransferase deficiency. Lancet ii:1283-1284.

    Google Scholar 

  • Kifune, A., Kubota, F., Shibata, N., Akata, T., and Kikuchi, S. (2000). Valproic acid-induced hyperammonemic encephalopathy with triphasic waves. Epilepsia 41:909-912.

    Google Scholar 

  • Koch, K.M., Wilensky, A.J., and Levy, R. H. (1989). Beta-oxidation of valproic acid. Effects of fasting and glucose in humans. Epilepsia 30:782-789.

    Google Scholar 

  • Laub, M.C. (1986). Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 27:55-59.

    Google Scholar 

  • Leao, M. (1995). Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency. Neurology 45:593-594.

    Google Scholar 

  • Lenn, N.J., Ellis, W.G., and Washburn, E.R. (1990). Fatal hepatocerebral syndrome in siblings discordant for exposure to valproate. Epilepsia 31:578-583.

    Google Scholar 

  • Marescaux, C., Warter, J.M., Micheletti, G., Rumbach, L., Coquillat, G., and Kurtz, D. (1982). Stuporous episodes during treatment with sodium valproate: Report of seven cases. Epilepsia 23:297-305.

    Google Scholar 

  • Marescaux, C., Warter, J.M., Laroye, M., Rumbach, L., Micheletti, G., Koehl, C., et al. (1983). Le valproate de sodium: une drogue Hyperammniémiante. Etude chez l'épileptique et chez le volontaire sain. J. Neurol. Sci. 58:195-198.

    Google Scholar 

  • Marini, A.M., Zaret, B.S., and Beckner, R.R. (1988). Hepatic and renal contributions to valproate-induced hyperammonemia. Neurology 38:365-371.

    Google Scholar 

  • Matsuda, I., Ohtani, Y., and Ninomiya, N. (1986). Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. J. Pediatr. 109:131-133.

    Google Scholar 

  • Murphy, J.V., and Marquardt, K. (1982). Asymptomatic hyperammonemia in patients receiving valproic acid. Arch. Neurol. 39:591-593.

    Google Scholar 

  • Noremberg, M.D. (1996). Astrocytic-ammonia interactions in hepatic encephalopathy. Semin. Liver Dis. 16:245-253.

    Google Scholar 

  • Oechsner, M., Steen, C., Sturenburg, H.J., and Kohlschutter, A. (1998). Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. J. Neurol. Neurosurg. Psychiatry 64:680-682.

    Google Scholar 

  • Ohtani, Y., Endo, F., and Matsuda, I. (1982). Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J. Pediatr. 101:782-785.

    Google Scholar 

  • Porter, R.J. (1984). Therapy: General considerations. In: Walton, J.N. (ed.), Major Problems in Neurology. Vol. 12: Epilepsy: 100 Elementary Principles, Saunders, London, p. 69.

    Google Scholar 

  • Ratnaike, R.N., Schapel, G.J., Purdie, G., Rischbieth, R.H.C., and Hoffmann, S. (1986). Hyperammonemia and hepatotoxicity during chronic valproate therapy: Enhancement by combination with other antiepileptic drugs. Br. J. Clin. Pharmacol. 22:100-103.

    Google Scholar 

  • Rumbach, L., Cremel, G., and Marescaux, C. (1989). Valproate-induced hyperammonemia of renal origin: Effects of valproate on gluatmine transport in rat kidney mitochondria. Biochem. Pharmacol. 38:3963-3967.

    Google Scholar 

  • Sackellares, J.C., Lee, S.I., and Dreifuss, F.E. (1979). Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia 20:697-703.

    Google Scholar 

  • Sakemi, K., and Takada, G. (1998). Effect of carnitine on valproic acid concentrations in serum, brain, and liver. Pediatr. Neurol. 18:331-333.

    Google Scholar 

  • Sakir, A., Vildan, B., Mehdi, T., Ozlem, H., Refik, B., and Levent, K. (1997). Asymptomatic hyperammonemia in children treated with valproic acid. J. Child Neurol. 12:461-463.

    Google Scholar 

  • Sato, S., White, B.G., and Penry, J.K. (1982). Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 2:157-159.

    Google Scholar 

  • Sherard, E.S., Steinman, G.S., and Couri, D. (1980). Treatment of childhood epilepsy with valproic acid: Result of the first 100 patients in a 6-month trial. Neurology 30:31-35.

    Google Scholar 

  • Sills, J.A., Trefor-Jones, R.H., and Taylor, W.H. (1980). Valproate, hyperammonemia and hyperglycinemia. Lancet ii:260-261.

    Google Scholar 

  • Stephens, J.R., and Levy, R.H. (1994). Effects of valproate and citrulline on ammonium-induced encephalopathy. Epilepsia 35:164-171.

    Google Scholar 

  • Thom, H., Carter, P.E., Cole, G.F., and Stevenson, K.L. (1991). Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev. Med. Child Neurol. 33:795-799.

    Google Scholar 

  • Verrotti, A., Greco, R., Morgese, G., and Chiarelli, F. (1999). Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int. J. Clin. Lab. Res. 29:36-40.

    Google Scholar 

  • Warter, J.M., Marescaux, C., Rumbach, L., Galmiche, J., Micheletti, G., Koehl, C., et al. (1981). L'hyperammoniémie isolée: une consequence fréquente des traitements par la valproate de sodium. Nouv. Presse Med. 10:3406-3409.

    Google Scholar 

  • Warter, J.M., Marescaux, C., Chabrier, G., Rumbach, L., Micheletti, G., Reitzer, B., et al. (1984). Increase of valproate-induced hyperammonemia in normal subjects by carbohydrate intake. Neurology 34:1487-1490.

    Google Scholar 

  • Williams, C.A., Tiefenbach, S., and McReynolds, J.W. (1984). Valproic acid-induced hyperammonemia in mentally retarded adults. Neurology 34:550-553.

    Google Scholar 

  • Wyllie, E., Wyllie, R., Rothner, A.D., Erenberg, G., and Cruse, R.P. (1983). Valproate-induced hyperammonemia in asymptomatic children. Cleve. Clin. Q. 50:275-278.

    Google Scholar 

  • Zaccara, G., Campostrini, R., Paganini, M., Messori, A., Valenza, T., Arnetoli, G., et al. (1984). Acute changes of blood ammonia may predict short-term adverse effects of valproic acid. Neurology 34:1519-1521.

    Google Scholar 

  • Zaccara, G., Campostrini, R., Paganini, M., Messori, A., Valenza, T., Arnetoli, G., et al. (1987). Long-term treatment with sodium valproate: Monitoring of venous ammonia concentrations and adverse effects. Ther. Drug Monit. 9:34-37.

    Google Scholar 

  • Zaret, B.S., Beckner, R. R., Marini, A. M., Wagle, W., and Passarelli, C. (1982). Valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology 32:206-209.

    Google Scholar 

Download references

Authors
  1. Alberto Verrotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela Trotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guido Morgese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Chiarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verrotti, A., Trotta, D., Morgese, G. et al. Valproate-Induced Hyperammonemic Encephalopathy. Metab Brain Dis 17, 367–373 (2002). https://doi.org/10.1023/A:1021918104127

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021918104127

Search

Navigation